Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12611000889954
Ethics application status
Approved
Date submitted
1/08/2011
Date registered
19/08/2011
Date last updated
3/12/2020
Date data sharing statement initially provided
3/12/2020
Date results provided
3/12/2020
Type of registration
Retrospectively registered

Titles & IDs
Public title
A Pilot Study of Deep Brain Stimulation for Treatment Resistant Major Depression
Scientific title
A pilot study to evaluate the effect of deep brain stimultion on the severity of depressive symptoms in patients with severe treatment resistant depression.
Secondary ID [1] 262737 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Treatment resistant major depression 270445 0
Condition category
Condition code
Mental Health 270592 270592 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Deep Brain Stimulation (DBS) using Medtronics Kinetra Model 7428.

DBS is a neurosurgical procedure that involves the precise implantation of very small electrodes into targeted regions of the brain. These electrodes are powered by a stimulating battery which is implanted under the skin in the chest. The type of stimulation that is delivered can be adjusted using an external remote control which is operated by the treating doctor.

The stimulation parameters include the combination of electrodes activated, electrode reference scheme, voltage, frequency and pulse width. In the current study all stimulation parameters will be individualised for each patient. They will be titrated over a period of weeks or months (depending on individual patient response) and once the optimal settings for each patient are identified stimulation will remain ongoing indefinitely.
Intervention code [1] 267083 0
Treatment: Devices
Intervention code [2] 269227 0
Treatment: Surgery
Comparator / control treatment
N/A
Control group
Uncontrolled

Outcomes
Primary outcome [1] 269334 0
Primary Outcome 1: change in severity of depressive symptoms, defined as:

Montgomery Asberg Depression Rating Scale
50% reduction = clinical response
<8 = clinical remission
Timepoint [1] 269334 0
Timepoint: baseline, post implantation / pre-stimulation onset, six months post stimulation onset, one year post stimulation onset.
Secondary outcome [1] 279399 0
Secondary Outcome 1: cognition as measured via standardised neuropsychology tasks.

- Repeatable Battery for the Assessment of Neuropsychological Status (RBANS; Versions A & B)

- Controlled Oral Word Association Test (FAS/CFL)

- Trail Making Test (A & B)

- Golden Stroop Test

- Letter Number Sequencing subtest (WAIS?III)
Timepoint [1] 279399 0
Timepoint: baseline, one year post stimulation onset
Secondary outcome [2] 279400 0
Secondary Outcome 2: Quality of life as measured via the Quality of Life Enjoyment and Satisfaction Scale: Short Form
Timepoint [2] 279400 0
Timepoint: baseline, post implantation / pre-stimulation onset, six months post stimulation onset, one year post stimulation onset.
Secondary outcome [3] 279401 0
Secondary Outcome 3: Social functioning as measured via the Social Adaptation Self-Evaluation Scale
Timepoint [3] 279401 0
Timepoint: baseline, post implantation / pre-stimulation onset, six months post stimulation onset, one year post stimulation onset.

Eligibility
Key inclusion criteria
1. Have a DSM-IV diagnosis of a major depressive episode as confirmed by both SCID interview and independent psychiatrist review (X2)

2. Age 18-70

3. Have treatment resistant depression at Stage V of the Thase and Rush classification. This is a very strict definition of TRD and requires failure to respond to adequate courses of at least several different classes of antidepressants and a course of bilateral ECT.

4. Have a Montgomery-Asberg Depression Rating Scale score of > 25 (moderate – severe depression)

5. Demonstration of capacity to give informed consent: this will need to be assessed and documented by two independent psychiatrists and signing of the consent form will take place in the presence of an independent consent monitor. Consent capacity will also be reviewed by the Victorian Psychosurgery Review Board.
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Have an unstable medical condition, neurological disorder or any history of a seizure disorder or are currently pregnant or lactating

2. Immediate suicide risk

3. Significant concurrent axis 1 or 11 psychiatric morbidity.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1 / Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
2/07/2007
Actual
2/07/2007
Date of last participant enrolment
Anticipated
Actual
1/06/2012
Date of last data collection
Anticipated
Actual
3/06/2013
Sample size
Target
10
Accrual to date
Final
6
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 267555 0
Hospital
Name [1] 267555 0
Monash Alfred Psychiatry Research Centre
Country [1] 267555 0
Australia
Funding source category [2] 267556 0
Commercial sector/Industry
Name [2] 267556 0
Medtronic Inc
Country [2] 267556 0
United States of America
Primary sponsor type
Hospital
Name
Monash Alfred Psychiatry Research Centre
Address
Alfred Hospital
First Floor Old Baker Building
Commercial Rd
Prahran VIC
3181
Country
Australia
Secondary sponsor category [1] 266611 0
None
Name [1] 266611 0
Address [1] 266611 0
Country [1] 266611 0
Other collaborator category [1] 252160 0
Individual
Name [1] 252160 0
Assoc Prof Richard Bittar
Address [1] 252160 0
Royal Melbourne Hospital
Grattan St
Parkville VIC
3050
Country [1] 252160 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 269517 0
Alfred Human Research and Ethics Committee
Ethics committee address [1] 269517 0
Ethics committee country [1] 269517 0
Australia
Date submitted for ethics approval [1] 269517 0
Approval date [1] 269517 0
22/06/2005
Ethics approval number [1] 269517 0
1/04/0151

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 32952 0
Prof Paul Fitzgerald
Address 32952 0
888 Toorak Rd Camberwell, Vic,
Country 32952 0
Australia
Phone 32952 0
+61 3 9805 4287
Fax 32952 0
Email 32952 0
[email protected]
Contact person for public queries
Name 16199 0
Paul Fitzgerald
Address 16199 0
888 Toorak Rd Camberwell, Vic,
Country 16199 0
Australia
Phone 16199 0
+61 3 9805 4287
Fax 16199 0
Email 16199 0
[email protected]
Contact person for scientific queries
Name 7127 0
Paul Fitzgerald
Address 7127 0
888 Toorak Rd Camberwell, Vic,
Country 7127 0
Australia
Phone 7127 0
+61 3 9805 4287
Fax 7127 0
Email 7127 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseA pilot study of bed nucleus of the stria terminalis deep brain stimulation in treatment-resistant depression.2018https://dx.doi.org/10.1016/j.brs.2018.04.013
N.B. These documents automatically identified may not have been verified by the study sponsor.